company background image
BNTX logo

BioNTech NasdaqGS:BNTX Stock Report

Last Price

US$88.96

Market Cap

US$21.7b

7D

-4.9%

1Y

-30.5%

Updated

29 Feb, 2024

Data

Company Financials +

BNTX Stock Overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

BNTX fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

BioNTech SE Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioNTech
Historical stock prices
Current Share PriceUS$88.96
52 Week HighUS$136.92
52 Week LowUS$88.00
Beta0.27
1 Month Change-6.34%
3 Month Change-10.50%
1 Year Change-30.49%
3 Year Change-6.51%
5 Year Changen/a
Change since IPO524.72%

Recent News & Updates

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

Feb 23

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Feb 09
BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Jan 18
Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Recent updates

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

Feb 23

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Feb 09
BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Jan 18
Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

Jan 02
Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Dec 11
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

Oct 22
Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Sep 11
BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Is BioNTech (NASDAQ:BNTX) A Risky Investment?

Jun 13
Is BioNTech (NASDAQ:BNTX) A Risky Investment?

A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

May 23
A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

Mar 29
BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely

Mar 05
These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely

A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Feb 18
A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates

Feb 02
Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates

With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

Jan 26
With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%

Nov 19
BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%

BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly

Nov 09
BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly

CDC advisory panel recommends COVID vaccines for children be included in federal program

Oct 19

Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?

Oct 18
Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?

Hong Kong approves BioNTech COVID vaccine for infants

Oct 12

EMA starts rolling review of Pfizer/BioNTech's Omicron-subvariant adapted shot for kids

Oct 03

BioNTech: A Tale Of 2 Companies

Sep 20

European drug regulator panel backs approval of Pfizer/BioNTech's Omicron-adapted shot

Sep 12

CDC advisors to vote on COVID Omicron vaccines on Sept. 1

Aug 30

Pfizer, BioNTech submit application to FDA for Omicron-specific COVID vaccine

Aug 22

BioNTech, Genmab expand pact to develop cancer immunotherapies

Aug 05

Pfizer-BioNTech's new Omicron/ancestral strain COVID vaccine enters phase 2 trial

Jul 27

Calculating The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Jul 25
Calculating The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Shareholder Returns

BNTXUS BiotechsUS Market
7D-4.9%4.2%1.8%
1Y-30.5%11.1%25.6%

Return vs Industry: BNTX underperformed the US Biotechs industry which returned 11.1% over the past year.

Return vs Market: BNTX underperformed the US Market which returned 25.6% over the past year.

Price Volatility

Is BNTX's price volatile compared to industry and market?
BNTX volatility
BNTX Average Weekly Movement4.8%
Biotechs Industry Average Movement11.8%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: BNTX's share price has been volatile over the past 3 months.

Volatility Over Time: BNTX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20085,700Ugur Sahinhttps://www.biontech.de

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors.

BioNTech SE Fundamentals Summary

How do BioNTech's earnings and revenue compare to its market cap?
BNTX fundamental statistics
Market capUS$21.73b
Earnings (TTM)US$2.97b
Revenue (TTM)US$7.15b

7.1x

P/E Ratio

3.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BNTX income statement (TTM)
Revenue€6.62b
Cost of Revenue€604.20m
Gross Profit€6.01b
Other Expenses€3.26b
Earnings€2.75b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Mar 20, 2024

Earnings per share (EPS)11.57
Gross Margin90.87%
Net Profit Margin41.57%
Debt/Equity Ratio0.01%

How did BNTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.